ANDREW J. ROBERTS;ZEHRA KAYMACALAN;HENDRICUS R.J.M. HOOGENBOOM;JOHN A. MANKOVICH;TRISTAN J. VAUGH;DEBORAH J. ALLEN;BORIS LABKOVSKY;BRIAN T. MCGUINNESS;DAVID SCHOENHAUT;JOCHEN G. SALFELD;PAUL SAKORAFAS
发明人:
JOCHEN G. SALFELD,DEBORAH J. ALLEN,HENDRICUS R.J.M. HOOGENBOOM,ZEHRA KAYMACALAN,BORIS LABKOVSKY,JOHN A. MANKOVICH,BRIAN T. MCGUINNESS,ANDREW J. ROBERTS,PAUL SAKORAFAS,DAVID SCHOENHAUT,TRISTAN J. VAUGH
申请号：
US13524525
公开号：
US20120258114A1
申请日:
2012.06.15
申请国别(地区):
US
年份:
2012
代理人:
摘要：
Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., Kd=10−8 M or less), a slow off rate for hTNFα dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
